earnings

NASDAQ · MRKR
Marker Therapeutics, Inc.
Healthcare · Biotechnology
$1.17
Down-$0.03 (-2.56%)
Updated Sep 16, 2026, 9:44 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 15.39M
- P/E ratio
- -1.67
- Dividend yield
- 0.00%
- 52-week range
- $1.05 – $1.79
- Volume
- 11.98K
- Avg. volume
- 265.93K
Price performance
MRKR price history
1M range · 20 trading sessions · Daily adjusted prices
MRKR closed at $1.17 after 20 trading sessions, up 1.74% for the selected period.
- Last close
- $1.17
- Period change
- +1.74%
- Period low
- $1.15
- Period high
- $1.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1.17 | $1.23 | $1.15 | $1.17 | 11.98K |
| Sep 14, 2026 | $1.16 | $1.2302 | $1.16 | $1.17 | 17.38K |
| Sep 11, 2026 | $1.20 | $1.245 | $1.10 | $1.15 | 59.37K |
| Sep 10, 2026 | $1.21 | $1.23 | $1.18 | $1.20 | 55.52K |
| Sep 9, 2026 | $1.29 | $1.29 | $1.21 | $1.21 | 71.16K |
| Sep 8, 2026 | $1.19 | $1.39 | $1.19 | $1.28 | 200.35K |
| Sep 4, 2026 | $1.25 | $1.3099 | $1.18 | $1.18 | 35.61K |
| Sep 3, 2026 | $1.24 | $1.3148 | $1.2235 | $1.24 | 43.43K |
| Sep 2, 2026 | $1.25 | $1.3303 | $1.24 | $1.25 | 167.58K |
| Sep 1, 2026 | $1.31 | $1.3362 | $1.255 | $1.30 | 21.03K |
| Aug 31, 2026 | $1.37 | $1.405 | $1.31 | $1.33 | 59.54K |
| Aug 28, 2026 | $1.50 | $1.50 | $1.35 | $1.37 | 84.79K |
| Aug 27, 2026 | $1.45 | $1.50 | $1.4001 | $1.46 | 24.51K |
| Aug 26, 2026 | $1.52 | $1.5905 | $1.45 | $1.45 | 33.84K |
| Aug 25, 2026 | $1.50 | $1.60 | $1.475 | $1.52 | 146.74K |
| Aug 24, 2026 | $1.44 | $1.53 | $1.41 | $1.50 | 238.04K |
| Aug 21, 2026 | $1.25 | $1.4399 | $1.25 | $1.39 | 99.38K |
| Aug 20, 2026 | $1.28 | $1.3227 | $1.19 | $1.22 | 80.6K |
| Aug 19, 2026 | $1.19 | $1.36 | $1.16 | $1.29 | 232.16K |
| Aug 18, 2026 | $1.16 | $1.18 | $1.15 | $1.15 | 46.14K |
Latest MRKR news
The latest Smart Investors Daily articles mentioning MRKR.
Stock researchResearch & News · SID Coverage
Loading stock research…

